Drug intelligence / Profile preview

Limosilactobacillus reuteri PBS072

Development stage: Preclinical
Lead developer: SynBalance
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Limosilactobacillus reuteri PBS072 is a specific strain of probiotic bacteria that has been investigated for a variety of health benefits, primarily related to the gut-brain axis. It is often studied in combination with another probiotic strain, Bifidobacterium breve BB077. Clinical and preclinical studies suggest its potential in mental health by reducing symptoms of depression and anxiety, particularly in the postpartum period. It has also been shown to help manage stress and improve sleep quality. In laboratory models using C. elegans, L. reuteri PBS072 demonstrated geroprotective effects, including extending lifespan and reducing markers of aging. The mechanism of action is believed to involve modulation of the gut microbiota, which in turn influences the gut-brain axis through pathways involving neurotransmitters like GABA and serotonin, and inhibition of the epigenetic enzyme LSD1. Additionally, it has shown in vitro antibacterial activity against oral pathogens.

Beyond the preview

Go deeper on Limosilactobacillus reuteri PBS072.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Limosilactobacillus reuteri PBS072.

Explore the full profile